These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 1496646)
1. Allogeneic bone marrow transplantation in the treatment of leukemia: emphasis on graft-vs-host disease and veno-occlusive disease in a Taiwan Chinese series. Chen YC; Lin KH; Wang CH; Tang JL; Lin MT; Lui LT; Lin DT; Tien HF; Lin KS Transplant Proc; 1992 Aug; 24(4):1526-8. PubMed ID: 1496646 [No Abstract] [Full Text] [Related]
2. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation--clinical and immunological considerations. Schlitt HJ; Tischler HJ; Ringe B; Raddatz G; Maschek H; Dietrich H; Kuse E; Pichlmayr R; Link H Bone Marrow Transplant; 1995 Sep; 16(3):473-8. PubMed ID: 8535323 [TBL] [Abstract][Full Text] [Related]
3. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver? Klaesson S; Ringdén O; Ljungman P; Aschan J; Hägglund H; Winiarski J Transplantation; 1995 Dec; 60(11):1225-30. PubMed ID: 8525515 [TBL] [Abstract][Full Text] [Related]
5. Graft-versus-leukemia activity after T-cell depletion using counterflow centrifugation. de Witte T; Preijers F; Schattenberg A Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():103-5. PubMed ID: 2202463 [No Abstract] [Full Text] [Related]
6. Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings. Mehta J; Powles R; Horton C; Milan S; Singhal S; Treleaven J Bone Marrow Transplant; 1995 Jun; 15(6):853-8. PubMed ID: 7581080 [TBL] [Abstract][Full Text] [Related]
7. Cytokines in veno-occlusive disease of the liver after bone marrow transplantation. Remberger M; Ringdén O Transplant Proc; 1995 Dec; 27(6):3533-4. PubMed ID: 8540087 [No Abstract] [Full Text] [Related]
8. Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Rozman C; Carreras E; Qian C; Gale RP; Bortin MM; Rowlings PA; Ash RC; Champlin RE; Henslee-Downey PJ; Herzig RH; Hinterberger W; Klein JP; Prentice HG; Reiffers J; Zwaan FE; Horowitz MM Bone Marrow Transplant; 1996 Jan; 17(1):75-80. PubMed ID: 8673059 [TBL] [Abstract][Full Text] [Related]
9. Association of hepatic veno-occlusive disease with interstitial pneumonitis in bone marrow transplant recipients. Wingard JR; Mellits ED; Jones RJ; Beschorner WE; Sostrin MB; Burns WH; Santos GW; Saral R Bone Marrow Transplant; 1989 Nov; 4(6):685-9. PubMed ID: 2819287 [TBL] [Abstract][Full Text] [Related]
10. Allogeneic bone marrow transplantation: acute and late complications. Tabbara IA Anticancer Res; 1996; 16(2):1019-26. PubMed ID: 8687093 [TBL] [Abstract][Full Text] [Related]
11. Treatment of leukemia by marrow transplantation from HLA incompatible donors. Effect of HLA-disparity on GVHD, relapse and survival. Hansen JA; Anasetti C; Beatty PG; Martin PJ; Sanders JE; Storb R; Thomas ED Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():108-11. PubMed ID: 2390636 [No Abstract] [Full Text] [Related]
12. Intravenous immunoglobulin: immune modulatory effects in vitro and clinical effects in allogeneic bone marrow transplant recipients. Klaesson S; Ringdén O; Markling L; Tammik L Transplant Proc; 1995 Dec; 27(6):3536-7. PubMed ID: 8540089 [No Abstract] [Full Text] [Related]
13. Early complications of bone marrow transplantation in children and adults. Tutschka PJ Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():22-6. PubMed ID: 2516755 [No Abstract] [Full Text] [Related]
14. Mixed chimerism after allogeneic bone marrow transplantation for leukemias. Bertheas MF; Lafage M; Blaise D; Stoppa AM; Viens P; Mannoni P; Maraninchi D Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():61-3. PubMed ID: 2390641 [No Abstract] [Full Text] [Related]
15. Immunobiology of bone marrow transplantation as treatment for hematologic malignancies. Champlin R Transplant Proc; 1991 Aug; 23(4):2123-7. PubMed ID: 1871828 [TBL] [Abstract][Full Text] [Related]
16. Alloimmune effects of bone marrow transplantation for leukaemia on the leukaemic diseases. Marmont AM Bone Marrow Transplant; 1991; 7 Suppl 2():2-3. PubMed ID: 1878696 [No Abstract] [Full Text] [Related]
17. Orthotopic liver transplantation for life-threatening veno-occlusive disease of the liver after allogeneic bone marrow transplant. Rapoport AP; Doyle HR; Starzl T; Rowe JM; Doeblin T; DiPersio JF Bone Marrow Transplant; 1991 Nov; 8(5):421-4. PubMed ID: 1768978 [TBL] [Abstract][Full Text] [Related]
18. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia. Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544 [TBL] [Abstract][Full Text] [Related]
19. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease. Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919 [TBL] [Abstract][Full Text] [Related]
20. Dissociating graft-vs-host disease from the graft-vs-leukemia effect of allogeneic T cells: the potential role of IL-2. Sykes M Bone Marrow Transplant; 1992; 10 Suppl 1():1-4. PubMed ID: 1521080 [No Abstract] [Full Text] [Related] [Next] [New Search]